CL2012001012A1 - Uso de compuestos de pirimidil aminobenzamida para el tratamiento de trastornos proliferativos y otras condiciones patológicas, en donde el medicamento se ajusta de una manera para tomarse justo antes del momento de irse a la cama; y paquete comercial que contiene una composicion farmaceutica que comprende al compuesto. - Google Patents

Uso de compuestos de pirimidil aminobenzamida para el tratamiento de trastornos proliferativos y otras condiciones patológicas, en donde el medicamento se ajusta de una manera para tomarse justo antes del momento de irse a la cama; y paquete comercial que contiene una composicion farmaceutica que comprende al compuesto.

Info

Publication number
CL2012001012A1
CL2012001012A1 CL2012001012A CL2012001012A CL2012001012A1 CL 2012001012 A1 CL2012001012 A1 CL 2012001012A1 CL 2012001012 A CL2012001012 A CL 2012001012A CL 2012001012 A CL2012001012 A CL 2012001012A CL 2012001012 A1 CL2012001012 A1 CL 2012001012A1
Authority
CL
Chile
Prior art keywords
treatment
pyrimidyl
drug
compound
adjusted
Prior art date
Application number
CL2012001012A
Other languages
English (en)
Inventor
Tomasz Szczudlo
Richard Woodman
Ophelia Yin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43222136&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012001012(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2012001012A1 publication Critical patent/CL2012001012A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Uso de compuestos derivados de pirimidil-amino-benzamida en el tratamiento de un trastorno proliferativo u otra condición patológica seleccionada de melanoma, cáncer de mama, cáncer de colon, cáncer de pulmón y cáncer de próstata o sarcoma de kaposi, entre otros; paquete comercial; y método de tratamiento.
CL2012001012A 2009-10-23 2012-04-20 Uso de compuestos de pirimidil aminobenzamida para el tratamiento de trastornos proliferativos y otras condiciones patológicas, en donde el medicamento se ajusta de una manera para tomarse justo antes del momento de irse a la cama; y paquete comercial que contiene una composicion farmaceutica que comprende al compuesto. CL2012001012A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25432309P 2009-10-23 2009-10-23

Publications (1)

Publication Number Publication Date
CL2012001012A1 true CL2012001012A1 (es) 2012-10-26

Family

ID=43222136

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012001012A CL2012001012A1 (es) 2009-10-23 2012-04-20 Uso de compuestos de pirimidil aminobenzamida para el tratamiento de trastornos proliferativos y otras condiciones patológicas, en donde el medicamento se ajusta de una manera para tomarse justo antes del momento de irse a la cama; y paquete comercial que contiene una composicion farmaceutica que comprende al compuesto.

Country Status (18)

Country Link
US (4) US20120202836A1 (es)
EP (1) EP2490690A1 (es)
JP (1) JP5948246B2 (es)
KR (2) KR101853596B1 (es)
CN (1) CN102647986A (es)
AU (3) AU2010310705A1 (es)
BR (1) BR112012009094A8 (es)
CA (1) CA2777019A1 (es)
CL (1) CL2012001012A1 (es)
IL (1) IL219109A (es)
MA (1) MA33666B1 (es)
MX (1) MX2012004709A (es)
NZ (1) NZ599217A (es)
RU (1) RU2012120901A (es)
TN (1) TN2012000150A1 (es)
TW (1) TWI592157B (es)
WO (1) WO2011050120A1 (es)
ZA (1) ZA201202413B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2776130A1 (en) 2011-11-07 2014-09-17 Institut National de la Sante et de la Recherche Medicale (INSERM) A ddr1 antagonist or an inhibitor of ddr1 gene expression for use in the prevention or treatment of crescentic glomerulonephritis
RU2014147017A (ru) 2012-04-24 2016-06-10 Чугаи Сейяку Кабусики Кайся Производное бензамида
AU2013253541A1 (en) * 2012-04-24 2014-11-20 Chugai Seiyaku Kabushiki Kaisha Quinazolinedione derivative
US9474753B2 (en) 2012-05-02 2016-10-25 Georgetown University Treating neural disease with tyrosine kinase inhibitors
CN105102983B (zh) * 2012-12-27 2017-08-08 奎斯特诊断投资股份有限公司 Ddr2突变作为黑素瘤或基底细胞癌的可靶向的特征
CN103965195B (zh) * 2013-02-01 2016-09-28 中国科学院广州生物医药与健康研究院 用于盘状结构域受体小分子抑制剂的化合物及其应用
CN105451752A (zh) * 2013-07-05 2016-03-30 因特格拉医学有限公司 口服组合物
JP6307088B2 (ja) 2013-10-23 2018-04-04 中外製薬株式会社 キナゾリノンおよびイソキノリノン誘導体
RU2018109255A (ru) * 2015-08-31 2019-10-04 Торэй Индастриз, Инк. Производное мочевины и его применение
WO2020207570A1 (en) * 2019-04-09 2020-10-15 Rottapharm Biotech S.R.L. Phenazines as inhibitors of discoidin domain receptors 2 (ddr2)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04012845A (es) 2002-06-28 2005-02-24 Nippon Shinyaku Co Ltd Derivado de amida.
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
CN101321532B (zh) * 2005-12-06 2011-06-29 诺瓦提斯公司 用于治疗神经纤维瘤病的嘧啶基氨基苯甲酰胺衍生物
US7729791B2 (en) * 2006-09-11 2010-06-01 Apple Inc. Portable media playback device including user interface event passthrough to non-media-playback processing
EP1923053A1 (en) * 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
BRPI0815330A2 (pt) * 2007-08-16 2017-05-09 Irm Llc métodos e composições para tratar cânceres

Also Published As

Publication number Publication date
NZ599217A (en) 2014-05-30
AU2016216636A1 (en) 2016-09-01
RU2012120901A (ru) 2013-12-10
US20140350037A1 (en) 2014-11-27
IL219109A0 (en) 2012-06-28
US20120202836A1 (en) 2012-08-09
CN102647986A (zh) 2012-08-22
EP2490690A1 (en) 2012-08-29
AU2016216636B2 (en) 2018-06-07
BR112012009094A8 (pt) 2017-10-10
KR20120099650A (ko) 2012-09-11
AU2010310705A1 (en) 2012-04-19
US20150313900A1 (en) 2015-11-05
US20170143716A1 (en) 2017-05-25
AU2014202963A1 (en) 2014-06-19
IL219109A (en) 2017-12-31
ZA201202413B (en) 2013-03-27
MX2012004709A (es) 2012-05-23
MA33666B1 (fr) 2012-10-01
JP5948246B2 (ja) 2016-07-06
JP2013508393A (ja) 2013-03-07
TN2012000150A1 (en) 2013-12-12
CA2777019A1 (en) 2011-04-28
BR112012009094A2 (pt) 2016-05-03
TWI592157B (zh) 2017-07-21
WO2011050120A1 (en) 2011-04-28
KR20170007868A (ko) 2017-01-20
TW201127383A (en) 2011-08-16
KR101853596B1 (ko) 2018-04-30

Similar Documents

Publication Publication Date Title
CL2012001012A1 (es) Uso de compuestos de pirimidil aminobenzamida para el tratamiento de trastornos proliferativos y otras condiciones patológicas, en donde el medicamento se ajusta de una manera para tomarse justo antes del momento de irse a la cama; y paquete comercial que contiene una composicion farmaceutica que comprende al compuesto.
CY1120521T1 (el) Παρασκευασμα προμειγματος δεξμεδετομιδινης
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
RU2019131148A (ru) Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
CL2012002319A1 (es) Compuestos derivados de amino-tienopirimidinas que contienen un grupo alquilo sustituido, inhibidores de mnk| o mnk2; composición farmacéutica; y su uso para la profilaxis o la terapia de enfermedades metabólicas, trastornos hematopoyéticos, enfermedades neurodegenerativas, cáncer, entre otras.
EP4360712A3 (en) Aryl- or heteroaryl-substituted benzene compounds
MX2012007098A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
MX2012007161A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
SG194469A1 (en) Tetrahydroquinoline derivatives useful as bromodomain inhibitors
CL2012002356A1 (es) Compuestos heterociclicos acidos derivados de ariltriazolonas ligadas a bisarilo, inhibidores de receptores de vasopresina v1a y v2; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar y/o prevenir insuficiencia cardiaca aguda y cronica, hiponatremia, entre otras.
EA201490891A1 (ru) Пиридопиразины, обладающие противораковой активностью через ингибирование fgfr киназ
EA201591402A1 (ru) Спиролактамные модуляторы nmda-рецептора и их применение
EA201591404A1 (ru) Спиролактамные модуляторы рецептора nmda и их применение
CL2011001094A1 (es) Compuesto derivados de pirazin-2-iloxi, inhibidores de pde10; composición farmacéutica que comprende a los compuestos; y uso de los compuestos en la preparación de medicamentos para tratar enfermedades, tales como obesidad, diabetes no dependiente de insulina, esquizofernia, bipolaridad, trastorno obsesivo-compulsivo y similares.
UA111717C2 (uk) Склад для перорального введення і ліпофільні солі метилналтрексону
CL2013001885A1 (es) Compuestos derivados de morfina, antagonistas del receptor ipiode periferico; composicion farmaceutica; formulacion oral; y uso para reducir los efectos colaterales de la terapia opioide (div. sol. 905-08).
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
UY34076A (es) Composición farmacéutica que contiene volasertib en dosificación mejorada y sus usos contra tumores sólidos avanzados
EA200701923A1 (ru) Лекарственная форма для перорального введения витамина
MX349254B (es) Compuestos para el tratamiento del sindrome metabolico.
TR200803522A1 (tr) Kolay kullanımlı inhalasyon cihazı.
CY1121238T1 (el) Παραγωγα παντοθενικου για την αντιμετωπιση νευρολογικων διαταραχων
ECSP13012453A (es) 2-oxi-quinolina-3-carboxamidas sustituidas como moduladores KCNQ2/3
UY34065A (es) Composición farmacéutica que contiene volasertib en dosificación mejorada y sus usos contra malignidades sólidas
MX2013012025A (es) Moduladores novedosos de neutransmision cortical dopaminergica y glutamatergica mediada por receptor de n-metil-d-aspartato.